(Q36503368)

English

Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria

scientific article published on April 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

1 reference

Europe PubMed Central

Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

diabetic nephropathy

1 reference

based on heuristic

inferred from title

Artur Beltrame Ribeiro

1

object named as

Artur Beltrame Ribeiro

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

author name string

Haralambos Gavras

2

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

publication date

1 April 2006

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

Arquivos Brasileiros de Endocrinologia e Metabologia

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

327-333

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

Irbesartan: an updated review of its use in cardiovascular disorders

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Olmesartan medoxomil

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Telmisartan: a review of its use in hypertension

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Safety of telmisartan in patients with arterial hypertension : an open-label observational study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Efficacy of valsartan in patients aged > or =65 years with systolic hypertension

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Systolic hypertension as a cardiovascular risk factor

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Angiotensin receptor blockade in the challenging era of systolic hypertension.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Clinical Advisory Statement. Importance of systolic blood pressure in older Americans

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Angiotensin II receptor antagonists and hypertension

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Comparative safety and tolerability of angiotensin II receptor antagonists

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Role of Angiotensin II AT1 Receptor Blockers in the Treatment of Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000200019

21 January 2018

Identifiers

10.1590/S0004-27302006000200019

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36503368&oldid=2177445940"